



Health, Seniors and Long-Term Care
Insurance Division
300 Carlton Street
Winnipeg, Manitoba Canada R3B 3M9

Information for Pharmacists

Claims Submission Procedure - Methadone ***Effective October 16, 2014***

Updated June 1, 2025

Please include this Procedure in your Drug Programs Information Network (DPIN) Manual under Section 4: Claims Submission.

- The Claims Submission Procedure - Methadone, which first came into effect on October 16, 2014:
 - enhances patient safety by ensuring a more consistent and clear indication in the patient's DPIN history of the dose of methadone prescribed for and dispensed to the patient; and
 - ensures a consistent process for adjudication and reimbursement of methadone preparations by Manitoba through DPIN.
- **NONE of the methadone, Methadose and/or Metadol-D 10 mg/ml Concentrate products are interchangeable with one another. Health Canada issued a [safety alert](#) in July 2020 advising that there may be a link between switching methadone-containing products used to treat opioid use disorder and the risk of lack of effect, which may present as withdrawal symptoms, which can lead to serious harms.** Pharmacists should refer to The College of Pharmacists of Manitoba (CPhM) for further information.
- **NONE of the Metadol*** and/or generic 1mg, 5mg, 10mg, 25mg methadone tablets are interchangeable with one another.** Pharmacists should refer to The College of Pharmacists of Manitoba (CPhM) for further information.

Methadone for Opioid Use Disorder:

- “Methadone powder in preparation of an oral solution”, PIN 909190, was delisted on October 22, 2015.
- Effective August 5, 2021, the following methadone products were listed as unrestricted Part 1 benefits:

Drug	DIN
JAMP methadone (sugar free) 10 mg/ml oral concentrate	02495783
ODAN methadone (cherry flavored) 10 mg/ml oral concentrate	02495872

ODAN methadone (sugar free, unflavored) 10 mg/ml oral concentrate	02495880
SANDOZ methadone (sugar free, cherry flavored) 10 mg/ml oral concentrate	02481979

- Additionally, effective June 1, 2025, the following methadone products will be listed as unrestricted Part 1 benefits:

Drug	DIN
PMS-methadone hydrochloride 10 mg/ml oral concentrate (dye-free, sugar-free, unflavored)	02552728
PMS-methadone hydrochloride 10 mg/ml oral concentrate (cherry flavored)	02552736

- Effective August 5, 2021, Methadose* and Metadol-D** 10 mg/ml Oral Concentrate were listed as Part 2 benefits:

Drug	DIN
Methadose* 10 mg/ml oral liquid	02394596
Methadose* Sugar Free 10mg/ml oral liquid	02394618
<u>Part 2 prescribing criteria:</u> <i>For treatment of patients who</i> <i>(a) are being treated with Methadose, or</i> <i>(b) have previously been treated with two or more methadone products listed under Part 1.</i>	
Metadol-D** 10 mg/ml oral concentrate	02244290
<u>Part 2 prescribing criteria:</u> <i>For treatment of patients who</i> <i>(a) are being treated with Metadol-D, or</i> <i>(b) have previously been treated with two or more methadone products listed under Part 1.</i>	

- Pharmacy operators must indicate the quantity of methadone dispensed as the total number of milliliters (ml) of methadone, Methadose*, or Metadol-D** dispensed.
- Pharmacy operators must specify in DPIN the total days' supply of methadone, Methadose*, or Metadol-D** provided to the patient.

- If a patient is dispensed methadone, Methadose*, or Metadol-D** carries, the total quantity of methadone, Methadose*, or Metadol-D** received by the patient must be entered into DPIN along with the correct days' supply. There should be a single entry into DPIN, and not separate entries on the same day.

For example: A prescription is presented for methadone 2240 mg to be dispensed as 80 mg OD for 28 days.

This can be entered as daily or weekly:

Daily	Weekly
Quantity Dispensed: 8 ml	Quantity dispensed: 56 ml
Days' Supply: 1	Days' Supply: 7

- Pharmacy operators will be reimbursed the ingredient cost plus professional fee.
- Pharmacy operators must record and keep a copy of the documentation in a retrievable manner, indicating how all calculations/billings were done, and tracking of all dosages dispensed.
- Methadone compounded into a capsule formulation is not a benefit through Manitoba.

Methadone for Pain Management:

- Metadol*** and generic methadone tablets are considered EDS benefits for the management of severe cancer related or chronic non-malignant pain that is not well controlled by short and long-acting morphine and hydromorphone as well as fentanyl products, and for use as a replacement for other narcotic analgesics in palliative care patients who are requiring frequent and continuous dosing of short-acting opiates.

Drug	DIN
Metadol*** 1mg tablet	02247698
Metadol*** 5mg tablet	02247699
Metadol*** 10mg tablet	02247700
Metadol*** 25mg tablet	02247701

Effective July 2, 2024, generic methadone tablets were listed as EDS benefits:

Drug	DIN
Apo-methadone 1mg tablet	02533642
Apo-methadone 5mg tablet	02533650
Apo-methadone 10mg tablet	02533669
Apo-methadone 25mg tablet	02533677

- NONE of the Metadol*** and/or generic 1mg, 5mg, 10mg, 25mg methadone tablets are interchangeable with one another. Pharmacists should refer to The College of Pharmacists of Manitoba (CPhM) for further information.
- Manitoba may conduct audits of the accounts and records of the pharmacy owner relating to methadone claims submitted by the pharmacy owner, to determine compliance with the terms and conditions of this procedure.

If your questions are not answered by reviewing the Claims Submission Procedures and FAQs posted at:
<https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html>

Please send an e-mail to PDPInfoAudit@gov.mb.ca.